CONMED stock sits at about US$33.83 after a very weak five year run, yet its valuation checks now point to a company that screens cheap on several measures. For investors, that contrast between long term share price weakness and a stronger valuation profile is the core question around CONMED today.

• CONMED shares have fallen about 74% over the past five years, which means the current price is being set after a prolonged period of weak returns.
• The key potential support for the valuation is whether CONMED can translate its medical equipment portfolio into steadier revenue and cash flow, while a major risk is that ongoing investment needs or margin pressure keep weighing on profitability.
• On Simply Wall St's broader checks, CONMED currently screens as undervalued in 5 of 6 areas, and you can see the full breakdown in the valuation scorecard.

The issue now is whether CONMED's current share price already reflects those risks, or if the weaker long term performance has pushed the stock below what its fundamentals may justify.

Does CONMED Look Undervalued on Earnings?

The P/E ratio is a common way to gauge how much investors are paying for each dollar of CONMED's earnings. At roughly 18.6x, CONMED's current P/E sits below the Medical Equipment industry average of about 25.6x and also below the broader peer group average of around 43.9x.

Simply Wall St's model estimates a fair P/E ratio of about 29.8x for CONMED, based on factors such as its sector, business profile and risk. This figure is materially higher than the current trading multiple, which indicates that the market is assigning a lower earnings multiple than this framework suggests.

On this P/E measure, CONMED stock currently appears undervalued.

The CONMED Narrative: What Would Justify Today's Price?

Simply Wall St Narratives take the valuation puzzle around CONMED and spell out which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. They sit on the company’s Community page. Each one presents CONMED's estimated fair value as a thesis about the business that you can track over time, rather than a one off snapshot.

One of the top community narratives on CONMED: 15% undervalued

"Margin expansion opportunities are significant as ongoing supply chain improvement initiatives, outsourcing to expert consultants, and realization of at least $20 million in annualized savings from operational efficiencies become fully recognized in the financials..."

Do you think there's more to the story for CONMED? Head over to our Community to see what others are saying!

The Bottom Line

CONMED now screens as undervalued on market multiples, with a P/E that sits well below both its industry and broader peer averages. That discount suggests investors are still cautious about how reliably the company can convert its medical equipment portfolio into consistent earnings and cash flow. For you, the key question is whether margin and investment pressures ease enough for the market to re rate the stock, or whether the lower multiple simply reflects enduring execution risk. The crux of the debate from here is whether CONMED can deliver steadier profitability without needing heavier spending that erodes that apparent value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.